PhRMA Statement on MedPAC Vote
WASHINGTON, D.C. (April 6, 2017) – Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Allyson Funk issued the following statement:
“PhRMA strongly opposes the wide range of new Medicare Part B recommendations approved by MedPAC earlier today. These recommendations could have a detrimental impact on access for patients who rely on Part B therapies to treat serious and complex conditions. These recommendations ignore the fact that medicines remain a small and stable share of overall spending while providing significant value to patients.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: